Information Provided By:
Fly News Breaks for March 4, 2020
NKTR
Mar 4, 2020 | 05:04 EDT
Barclays analyst Peter Lawson initiated coverage of Nektar Therapeutics with an Overweight rating and $30 price target.
News For NKTR From the Last 2 Days
There are no results for your query NKTR